Lourd Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Lourd Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,847	Closed	-$221K	–	347
2017 Q4	$221K	Buy	+1,847	New	+$225K	0.01%	315

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lourd Capital's ALXN Position: Q1 2018 in Review

Lourd Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 1,847 shares — an estimated $221K sold.

Lourd Capital first reported a position in ALXN in Q4 2017 and held it in 1 quarter. The position peaked at $221K in Q4 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

Lourd Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Lourd Capital sold 1,847 Alexion Pharmaceuticals shares in Q1 2018, an estimated $221K.
Lourd Capital first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Lourd Capital's Alexion Pharmaceuticals position peaked at $221K in Q4 2017.
596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Lourd Capital's 13F filing for Q1 2018, filed 10 Apr 2018.